Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.
Conclusions: Available evidence of off-label rituximab use for the treatment of patients with RRMS suggests generally favorable efficacy versus placebo and interferons/glatiramer acetate; however, the poor quality of the included studies limits any robust conclusions.
PMID: 32129684 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Copaxone | Databases & Libraries | Disability | Multiple Sclerosis | Research | Rituxan | Statistics | Study